Home > For Consumers > No evidence of benefit of partial liquid...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-. doi: 10.1002/14651858.CD003707.pub3

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

No evidence of benefit of partial liquid ventilation in adults with acute lung injury and some evidence of increased risk associated with its use

This version published: 2013; Review content assessed as up-to-date: November 12, 2012.

Link to full article: [Cochrane Library]

Plain language summary

Seriously ill adults can get a severe lung disease called acute lung injury or acute respiratory distress syndrome, which stops enough oxygen from getting into the blood. About half of these patients die, and for those who survive, it can take several years to get back to near normal.

At the height of their illness, many of these patients are unable to breathe properly and need the assistance of a breathing machine called a ventilator, which pushes gas into the lungs under pressure through a process called artifical ventilation. Artifical ventilation can cause further damage to the lungs. The need to support breathing for these patients, while avoiding further lung damage, has led to a search for gentler types of ventilation.

One such gentler type of ventilation is called partial liquid ventilation. It uses a special liquid called perfluorocarbon instead of the gas used by traditional ventilators.

The purpose of this systematic review was to determine whether patients with acute lung injury who received partial liquid ventilation were less likely to die or were more likely to recover completely than those who received traditional gas ventilation.

To provide the best possible answer to this question, this review was conducted in a special preplanned way with the intention of putting together the results of all selected studies to produce an overall measure of the value of partial liquid ventilation. Two eligible studies (including a total of 401 participants) were found, and a comparison was made between those who received similar doses of perfluorocarbon and those who received traditional ventilation. No evidence indicated that partial liquid ventilation reduced the risk of death or the duration of artifical ventilation, and some evidence suggested that it may increase the risk of complications, including low blood oxygen levels, low heart rate, low blood pressure, air leakage from the lungs and cardiac collapse.

Abstract

Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are syndromes of severe respiratory failure that are associated with substantial mortality and morbidity. Artifical ventilatory support is commonly required and may exacerbate lung injury. Partial liquid ventilation (PLV) has been proposed as a less injurious form of ventilatory support for these patients. Although PLV has been shown to improve gas exchange and to reduce inflammation in experimental models of ALI, a previous systematic review did not find any evidence to support or refute its use in humans with ALI and ARDS.

Objectives: The primary objective of this review was to assess whether PLV reduced mortality (at 28 d, at discharge from the intensive care unit (ICU), at discharge from hospital and at one, two and five years) in adults with ALI or ARDS when compared with conventional ventilatory support.

Secondary objectives were to determine how PLV compared with conventional ventilation with regard to duration of invasive mechanical ventilation, duration of respiratory support, duration of oxygen therapy, length of ICU stay, length of hospital stay, incidence of infection, long‐term cognitive impairment, long‐term health related quality of life, long‐ term lung function, long‐term morbidity costs and adverse events. The following adverse events were considered: hypoxia (arterial PO2 <80 mm Hg), pneumothorax (any air leak into the pleural space requiring therapeutic intervention), hypotension (systolic blood pressure < 90 mm Hg sustained for longer than two minutes or requiring treatment with fluids or vasoactive drugs), bradycardia (heart rate < 50 beats per minute sustained for longer than one minute or requiring therapeutic intervention) and cardiac arrest (absence of effective cardiac output).

Search methods: In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 10, 2012, in The Cochrane Library; MEDLINE (Ovid SP, 1966 to November 2012); EMBASE (Ovid SP, 1980 to November 2012) and CINAHL (EBSCOhost,1982 to November 2012) for published studies. In our original review, we searched until May 2004.

Grey literature was identified by searching conference proceedings and trial registries and by contacting experts in the field.

Selection criteria: As in the original review, review authors selected randomized controlled trials that compared PLV with other forms of ventilation in adults (16 y of age or older) with ALI or ARDS, reporting one or more of the following: mortality; duration of mechanical ventilation, respiratory support, oxygen therapy, stay in the intensive care unit or stay in hospital; infection; long‐term cognitive impairment or health‐related quality of life; long‐term lung function or cost.

Data collection and analysis: Two review authors independently evaluated the quality of the relevant studies and extracted the data from included studies.

Main results: In this updated review, one new eligible study was identified and included, yielding a total of two eligible studies (including a combined total of 401 participants). Of those 401 participants, 170 received 'high'‐dose partial liquid ventilation (i.e. a mean dose of at least 20 mL/kg), 99 received 'low‐dose' partial liquid ventilation (i.e. a dose of 10 mL/kg) and 132 received conventional mechanical ventilation (CMV). Pooled estimates of effect were calculated for all those who received 'high'‐dose PLV versus conventional ventilation. No evidence indicated that 'high'‐dose PLV either reduced mortality at 28 d (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.79 to 1.85, P = 0.37) or increased the number of days free of CMV at 28 d (mean difference (MD) ‐2.24, 95% CI ‐4.71 to 0.23, P = 0.08). The pooled estimate of effect for bradycardia in those who received PLV was significantly greater than in those who received CMV (RR 2.51, 95% CI 1.31 to 4.81, P = 0.005). Pooled estimates of effect for the following adverse events-hypoxia, pneumothorax, hypotension and cardiac arrest-all showed a nonsignificant trend towards a higher occurrence of these events in those treated with PLV. Because neither eligible study addressed morbidity or mortality beyond 28 d, it was not possible to determine the effect of PLV on these outcomes.

Authors' conclusions: No evidence supports the use of PLV in ALI or ARDS; some evidence suggests an increased risk of adverse events associated with its use.

Editorial Group: Cochrane Anaesthesia Group.

Publication status: Edited (no change to conclusions).

Citation: Galvin IM, Steel A, Pinto R, Ferguson ND, Davies MW. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD003707. DOI: 10.1002/14651858.CD003707.pub3. Link to Cochrane Library. [PubMed: 23881653]

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 23881653

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...